You are here: Industry Insights > Market News > Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Jackfruit Powder

Pineapple Powder

Musang King Durian Powder

Noni Enzyme Powder

VITAMIN B12

hydraulic column packer/protein chromatography column/prepacked gel column packer

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

www.nmpa.comJanuary 04, 2023

Tag: Ainuovirine , lamivudine

Favorites

Recently, the innovative drug Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (trade name:復(fù)邦德) of Jiangsu Aidea Pharmaceutical Co., Ltd. is approved by China NMPA. This product is a compound medicine composed of Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate, which is indicated for the treatment of adult HIV-1 infected patients.

The marketing of this drug provides new treatment options for adult HIV-1 infected patients.

Previous:Mobocertinib succinate capsules approved for marketing with conditions

Next:China, New Zealand to further enhance science cooperation

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

InnoCare Pharma announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment patients with non-segmental vitiligo in China.

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing - PharmaSources.com

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

PR NewswireMay 14, 2025

iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, announced the first use of the iotaSOFT? Insertion System outside of the United States.

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

Related News

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

You may like
More>>

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

Related News

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

You may likeMore>>

You may like
More>>